Peripheral Blood Stem Cell Harvest HPC Count Is an Effective Surrogate Marker for CD34+ Cell Count in Allogeneic Stem Cell Transplant Setting

Jamal, Ammarah; Khan, Mohammad Tahir; Parveen, Sadia; Rizvi, Qurratulain; Farzana, Tasneem; Zaidi, Uzma; Borhany, Munira; Siddiqui, Saima; Ansari, Saqib Hussain; Shamsi, Tahir

doi:10.1016/j.tranon.2020.100788

Cited by 7 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The profile of the transplant program, including type of donor, source of cells, and choice of conditioning regimen, is fully comparable to the trends and data presented by other transplant centers [13]. The median infused amount of HSC, defined as CD34+ x 10^6/kg and hematological recovery, meet the target levels for AlloSCT from peripheral blood [14]. The results of the transplantation program in our center for the study period, evaluated as OS, PFS, CIR, NRM, and the frequency of post-transplant complications -aGVHD, cGVHD, and CMV reactivation, correspond to those cited in the literature.…”

Section: Discussionsupporting

confidence: 52%

Risk Factors for the Outcome After Allogeneic Stem Cell Transplantation: A Single-Center Exeperience

Milcheva,

Yankova,

Lazarova

et al. 2019

View full text Add to dashboard Cite

Allogeneic stem cell transplantation (AlloSCT) is a therapeutic procedure for the treatment of a large number of malignant and non-malignant hematological diseases, unfortunately still associated with significant morbidity and mortality. Disease relapse and non-relapse mortality remain the main causes of treatment failure following AlloSCT. Identification of the risk factors associated with this continue to be a subject of extensive scientific research. The aim of our study is to estimate the risk factors that would have prognostic significance for the outcome of AlloSCT for our patient population. We evaluated 96 patients who received AlloSCT in the transplant unit at Specialized Hospital for Active Treatment of Hematological Diseases (SHATHD), between 2017-2022, with the following diagnoses: acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL.They were prospectively followed up to June 2023. Our results regarding success rates and

show abstract

Section: Discussionsupporting

confidence: 52%

Risk Factors for the Outcome After Allogeneic Stem Cell Transplantation: A Single-Center Exeperience

Milcheva,

Yankova,

Lazarova

et al. 2019

View full text Add to dashboard Cite

show abstract

“…G-CSF monotherapy or plerixafor) was selected most frequently. Recently, Jamal et al reported a cut-off value of ≥1.8×10 6 /kg AP-HPC for predicting a CD34 + count of 2×10 6 /kg in healthy donors in an allogeneic transplantation setting ( 26 ). This value is markedly lower than that obtained in the present study.…”

Section: Discussionmentioning

confidence: 99%

“…Measurement of the PB-CD34 + count is a more firmly established method for predicting the AP-CD34 + count, and in facilities where rapid CD34 + measurement is available, it is an ideal indicator (20)(21)(22)(23)(24)(25). Compared to PB-HPCs, only a few reports have proposed the use of AP-HPCs in clinical practice (26). This may be because the measurement of the AP-CD34 + count can never be omitted, being essential for determining whether or not autologous transplantation can proceed.…”

Section: Discussionmentioning

confidence: 99%

Hematopoietic Progenitor Cell Counts of the Leukapheresis Product Determined Using Sysmex XN Analyzers Predict a Sufficient Number of CD34<sup>+</sup> Stem Cells in a Peripheral Blood Stem Cell Harvest for Autologous Transplantation

et al. 2024

View full text Add to dashboard Cite

Objective Several institutions outsource CD34 + cell counting of leukapheresis products, limiting rapid measurements, as results are obtained the next day. This problem is compounded with plerixafor use, a stem cell-mobilizing drug that increases leukapheresis efficiency but requires administration the day before leukapheresis. Use of this drug for a second leukapheresis procedure before the first-day leukapheresis CD34 + count results are confirmed causes unnecessary leukapheresis and expensive plerixafor administration. We investigated whether or not measuring hematopoietic progenitor cells in leukapheresis products (AP-HPCs) using a Sysmex XN-series analyzer could resolve this problem. Methods We retrospectively compared the absolute AP-HPC value per body weight with the CD34 + (AP-CD34 + ) count in 96 first-day leukapheresis product samples obtained between September 2013 and January 2021. Comparisons were also conducted according to regimen: granulocyte colony-stimulating factor (G-CSF) monotherapy, chemotherapy plus G-CSF, or plerixafor mobilization. Results AP-CD34 + and AP-HPC counts correlated strongly (r s =0.846) overall and, in particular, under chemotherapy plus G-CSF (r s =0.92) but correlated mildly under G-CSF monotherapy (r s =0.655). AP-HPCs could not completely be dichotomized based on an AP-CD34 + threshold of 2×10 6 /kg for any stimulation procedure. In most cases with AP-HPCs ＞6×10 6 /kg, the AP-CD34 + count exceeded 2.0×10 6 /kg, but in 5.7% of these cases, the AP-CD34 + count was ＜2.0×10 6 /kg. A cut-off of AP-HPCs ＞4.843×10 6 /kg yielded a sensitivity of 71% and specificity of 96% for predicting AP-CD34 + ≥2×10 6 /kg. Conclusion AP-HPCs can identify cases in which sufficient stem cells have been collected.

show abstract

“…2 However, the success of peripheral HPSC is reliant on obtaining an adequate number of hematopoietic stem cells to ensure satisfactory hematological reconstitution. 3,4 CD34+ is a marker of HPSC, and all colony-forming activity of human bone marrow 5 and it is agreed that a minimum of ≥2 Â 10 6 /kg CD34+ of recipient body weight is necessary for successful engraftment 6 in the autologous setting, however more cells are required in the allogenic setting. Although there is an agreed minimum value, the target for CD34+ can vary between institutions, type of disease and the type of transplant being performed.…”

Section: Introductionmentioning

confidence: 99%

The efficiency of a continuous versus an intermittent apheresis method for collection of hematopoietic progenitor stem cells: A systematic review

Hobbs

Green

Fernandez

2023

J of Clinical Apheresis

View full text Add to dashboard Cite

Peripheral blood hematopoietic progenitor stem cells (HPSCs) are the most common source of stem cells for autologous and allogenic transplantation. Currently, systematic reviews comparing the collection efficiency of a continuous to an intermittent method are lacking despite the existence of primary studies. Therefore, the objective of this review was to synthesize the best available evidence to compare the efficiency of the continuous vs the intermittent method for the collection of hematopoietic progenitor stem cells required for HPC transplantation. A search using MEDLINE, CINAHL, EMBASE, Google scholar, and MedNar for both published and unpublished studies was conducted in December 2021. The systematic review was conducted in accordance with JBI methodology. A critical appraisal of the studies was undertaken by two independent reviewers using the JBI quasi-experimental critical appraisal checklist. A total of six studies were included in the review. The findings of this review demonstrated that there was no statistically significant difference in the collection efficiency, length of procedure time, and total blood volume processed between the continuous and intermittent programs. The evidence suggests that the continuous method is as safe and effective as the intermittent method to collect HPSCs. Until further evidence becomes available clinicians should be guided by the policies of their individual hospitals.

show abstract

Peripheral Blood Stem Cell Harvest HPC Count Is an Effective Surrogate Marker for CD34+ Cell Count in Allogeneic Stem Cell Transplant Setting

Cited by 7 publications

References 24 publications

Risk Factors for the Outcome After Allogeneic Stem Cell Transplantation: A Single-Center Exeperience

Risk Factors for the Outcome After Allogeneic Stem Cell Transplantation: A Single-Center Exeperience

Hematopoietic Progenitor Cell Counts of the Leukapheresis Product Determined Using Sysmex XN Analyzers Predict a Sufficient Number of CD34<sup>+</sup> Stem Cells in a Peripheral Blood Stem Cell Harvest for Autologous Transplantation

The efficiency of a continuous versus an intermittent apheresis method for collection of hematopoietic progenitor stem cells: A systematic review

Contact Info

Product

Resources

About